S1P signaling: New therapies and opportunities

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Gonzalez Cabrera, Pedro J ^a   Brown, Steve ^a   Studer, Sean M ^a   Rosen, Hugh ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERALIFIMOD; FINGOLIMOD; PONESIMOD; SIPONIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ARTICLE; CYTOKINE STORM; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOMODULATION; IMMUNOSURVEILLANCE; INFLAMMATORY BOWEL DISEASE; LUPUS VULGARIS; MULTIPLE SCLEROSIS; MURINE MODEL; NONHUMAN; PSORIASIS; SIGNAL TRANSDUCTION; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRAL RESPIRATORY TRACT INFECTION;

EID: 84914809927     PISSN: 20517599     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-109     Document Type: Article

References (39)

1. Radue E, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, Vera A de, Zhang-Auberson L, Francis G, Burtin P, Kappos L: Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of neurology 2012, 69:1259-69.
2. Kira J, Itoyama Y, Kikuchi S, Hao Q, Kurosawa T, Nagato K, Tsumiyama I, Rosenstiel P von, Zhang-Auberson L, Saida T: Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC neurology 2014, 14:21.
3. Chun J, Brinkmann V: A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discovery medicine 2011, 12:213-28.
4. Chun J, Hartung H: Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clinical neuropharmacology 2010, 33:91-101.
5. Choi JW, Gardell SE, Herr DR, Rivera R, Lee C, Noguchi K, Teo ST, Yung YC, Lu M, Kennedy G, Chun J: FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:751-6.
6. 1-degradative mechanisms leads to vascular leak in mice. The Journal of clinical investigation 2011, 121:2290-300.
7. Gonzalez-Cabrera PJ, Cahalan SM, Nguyen N, Sarkisyan G, Leaf NB, Cameron MD, Kago T, Rosen H: S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis. Molecular pharmacology 2012, 81:166-74.
8. Roberts E, Guerrero M, Urbano M, Rosen H: Sphingosine 1-phosphate receptor agonists: a patent review (2010-2012). Expert opinion on therapeutic patents 2013, 23:817-41.
9. Selmaj K, Li, David KB, Hartung H, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke F, Wallström E: Siponimod for patients with relapsing-remittingmultiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. The Lancet. Neurology 2013, 12:756-67.
10. Altwegg R, Vincent T: TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease. Mediators of inflammation 2014, 2014:172821.
11. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel J: Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008, 57:549-58.
12. Shimizu H, Takahashi M, Kaneko T, Murakami T, Hakamata Y, Kudou S, Kishi T, Fukuchi K, Iwanami S, Kuriyama K, Yasue T, Enosawa S, Matsumoto K, Takeyoshi I, Morishita Y, Kobayashi E: KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 2005, 111:222-9.
13. Scheinin T, Butler DM, Salway F, Scallon B, Feldmann M: Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis. Clinical and experimental immunology 2003, 133:38-43.
14. Rennick D, Davidson N, Berg D: Interleukin-10 gene knock-out mice: a model of chronic inflammation. Clinical immunology and immunopathology 1995, 76:S174-8.
15. Song J, Matsuda C, Kai Y, Nishida T, Nakajima K, Mizushima T, Kinoshita M, Yasue T, Sawa Y, Ito T: Anovel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. The Journal of pharmacology and experimental therapeutics 2008, 324:276-83.
16. Sanada Y, Mizushima T, Kai Y, Nishimura J, Hagiya H, Kurata H, Mizuno H, Uejima E, Ito T: Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis. PloS one 2011, 6:e23933.
17. Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, Masuyama J, Fujimura A, Kobayashi E, Kano S, Minota S: Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. The Journal of rheumatology 2002, 29:707-16.
18. Wenderfer SE, Stepkowski SM, Braun MC: Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist. Kidney international 2008, 74:1319-26.
19. Brossard P, Scherz M, Halabi A, Maatouk H, Krause A, Dingemanse J: Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: Favorable impact of dose up-titration. Journal of clinical pharmacology 2014.
20. Olsson T, Boster A, Fernández O, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller MS, Sidorenko T, Radue E, Melanson M: Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. Journal of neurology, neurosurgery, and psychiatry 2014, 85:1198-208.
21. Marsolais D, Hahm B, Edelmann KH, Walsh KB, Guerrero M, Hatta Y, Kawaoka Y, Roberts E, Oldstone MB, Michael BA, Rosen H: Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza. Molecular pharmacology 2008, 74:896-903.
22. Walsh KB, Teijaro JR, Rosen H, Oldstone MB, Michael BA: Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm. Immunologic research 2011, 51:15-25.
23. Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, Scott F, Martinborough E, Peach R, Oldstone MB, Michael BA, Rosen H: Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 2011, 146:980-91.
24. Teijaro JR, Walsh KB, Long JP, Tordoff KP, Stark GV, Eisfeld AJ, Kawaoka Y, Rosen H, Oldstone MB, Michael BA: Protection of ferrets from pulmonary injury due to H1N1 2009 influenza virus infection: immunopathology tractable by sphingosine-1-phosphate 1 receptor agonist therapy. Virology 2014, 452-453:152-7.
25. Teijaro JR, Walsh KB, Rice S, Rosen H, Oldstone MB, Michael BA: Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proceedings of the National Academy of Sciences of the United States of America 2014, 111:3799-804.
26. Pardi DS, Sandborn WJ: Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? Gut 2005, 54:321-2.
27. Loftus EV, Davis KL, Wang C, Dastani H, Luo A: Treatment patterns, complications, and disease relapse in a real-world population of patients with moderate-to-severe ulcerative colitis initiating immunomodulator therapy. Inflammatory bowel diseases 2014, 20:1361-7.
28. Lépine S, Allegood JC, Park M, Dent P, Milstien S, Spiegel S: Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced autophagy. Cell death and differentiation 2011, 18:350-61.
29. Maceyka M, Spiegel S: Sphingolipid metabolites in inflammatory disease. Nature 2014, 510:58-67.
30. Snider AJ, Kawamori T, Bradshaw SG, Orr KA, Gilkeson GS, Hannun YA, Obeid LM: A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 2009, 23:143-52.
31. Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang W, Hait NC, Allegood JC, Price MM, Avni D, Takabe K, Kordula T, Milstien S, Spiegel S: Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer cell 2013, 23:107-20.
32. Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis [http://ir.receptos.com/releasedetail.cfm?ReleaseID=878411].
33. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, Luo C, Marmorstein R, Kordula T, Milstien S, Spiegel S: Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science (New York, NY) 2009, 325:1254-7.
34. Kharel Y, Lee S, Snyder AH, Sheasley-O'neill SL, Morris MA, Setiady Y, Zhu R, Zigler MA, Burcin TL, Ley K, Tung KS, Kenneth SK, Engelhard VH, Macdonald TL, Pearson-White S, Lynch KR: Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. The Journal of biological chemistry 2005, 280:36865-72.
35. Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, van Echten-Deckert G, Hajdu R, Rosenbach M, Keohane CA, Mandala S, Spiegel S, Proia RL: Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. The Journal of biological chemistry 2004, 279:52487-92.
36. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A: Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. The Lancet. Neurology 2014, 13:657-65.
37. 3) in rat. PloS one 2012, 7:e52985.
38. Moberly JB, Ford DM, Zahir H, Chen S, Mochizuki T, Truitt KE, Vollmer TL: Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients. Journal of neuroimmunology 2012, 246:100-7.
39. Olson A, Hartung J, Timony G, Peach R, Boehm M, Smith H, Gujrathi S: P356 Safety and PK results of a thorough QT/QTc (TQT) study of orally administered RPC1063, a novel, selective S1P1 receptor agonist. Journal of Crohn's and Colitis 2014, 8:S213.